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Background: Tuberculosis is a highly contagious disease, and there has been a rise in recent years of drug-resistant
cases no longer responding to standard treatment.
In order to address this threat and contain possible transmission of drug-resistant cases, some countries have taken
strong action, including the compulsory detention of non-adherent drug-resistant patients. These measures have
been strongly criticized by human rights advocates, and they raise the question of how to legally protect both
citizens and the community.
Discussion: Following discussions with National Tuberculosis Programs in Africa (the continent with the highest
incidence rates of tuberculosis worldwide), we show that of all the countries surveyed, all but one (Swaziland) had
either no specific policy addressing tuberculosis, or only general policies regarding public health applicable to
tuberculosis. Six countries also reported having policies that address non-adherence to treatment with containment
(isolation in health facilities or incarceration), but laws are not adequately enforced. If the international community
wants to effectively respond to the threat of tuberculosis transmission, there is a need to go beyond national tuberculosis
policies and to implement an international framework for tuberculosis control, inspired by the Framework Convention on
Tobacco Control, a key model for future public health treaties that address global burdens of disease. The framework,
for which we clarify the conditions and procedures in this piece, would define the rights and responsibilities of the
different stakeholders involved: patients, doctors, pharmaceutical firms and public authorities. To facilitate the
governance of the national obligations under the Convention, a coordinating body should be set up, under the
leadership of the World Health Organization and the Stop TB Partnership.
Summary: Successfully implementing policies for tuberculosis that simultaneously address patients’ rights and
communities’ wellbeing will have positive implications for those affected by the disease and serve as a basis for other
global health conventions to truly ensure the global right to health.
Keywords: Tuberculosis, Drug-resistant tuberculosis, Framework convention, Human rightsBackground
Overview of tuberculosis
Tuberculosis (TB) kills more than 3,500 people each day
worldwide, leading to approximately 1.3 million deaths
yearly [1]. One third of the world’s population is in-
fected, and 8.6 million new cases of active TB are es-
timated to occur around the world each year. TB is
highly contagious: each person with active TB, if left* Correspondence: yba2101@columbia.edu
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unless otherwise stated.untreated, will infect an average of ten to fifteen people
annually [2].
Most cases of TB are drug-susceptible, therefore curable.
However, there has been a rise in recent years of drug-
resistant cases that no longer respond to standard TB anti-
biotics. Multidrug-resistant TB (MDR-TB), estimated at
450,000 cases a year worldwide [3], or the virtually incur-
able extensively drug-resistant TB (XDR-TB), have been
detected in every part of the world [4]. In an effort to re-
spond to this threat and contain possible transmission of
drug-resistant TB within communities, some countries
such as Kenya and South Africa have taken strong actions,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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MDR-TB and XDR-TB patients [5]. In Kenya, two non-
adherent TB patients were deemed a public health threat
to their communities and incarcerated for several months
in 2010 [6]. In 2012 in the Unites States, a California man
infected with tuberculosis was charged and jailed for not
taking his TB medication [7]. Such measures have been
strongly criticized by human rights advocates and inter-
national organizations that denounce a violation of human
rights for patients who are punished for the inadequacy of
the health systems [8].
The World Health Organization and International Public
Health Frameworks
International agencies including the World Health
Organization (WHO) and the Center for Disease Control
and Prevention (CDC) have issued policy recommenda-
tions on how to better balance global public health
and individual rights in managing TB [9-11]. The WHO
specifically has the ability to disseminate regulations and
agreements on international healtha, including standards
related to “quarantine requirements…to prevent the inter-
national spread of diseaseb,” and the ability to oversee any
national health legislation promulgated in each member
state’s jurisdictionc. The WHO is also in a unique pos-
ition as an international organization: per its Constitution,
it can draft conventions that are binding on all signatory
member statesd.
However, the WHO has only asserted this authority
once, in the Framework Convention on Tobacco Control
(FCTC) of 2003 [12,13]. While international guidelines
on TB prevention, care and control exist [10], there are
no legally binding standards to ensure that states are ac-
tually implementing the required guidelines. This raises
the question of how to create enforceable guidelines and
policies that will protect citizens and the international
community. Can a TB control framework be implemented
by different countries under the auspices of the WHO and
the Stop TB partnership? Is there even a need for an inter-
national legal framework specific to TB? How would this
proposed framework balance rights of the individual and
the rights of the collective, or more broadly, take into ac-
count public health concerns?
The right to health
Since the 20th century, human rights have increasingly be-
come a central preoccupation of the international commu-
nity [14]. Several instruments were adopted to codify and
protect human rights, including the Universal Declaration of
Human Rights (UDHR) of 1948 [15], and the International
Covenant on Economic, Social and Cultural Rights
(ICESCR) of 1966, which recognizes in its 12th Article
“the right of everyone to the enjoyment of the highest
attainable standard of physical and mental health”[16]. Currently, every state in the world has signed on to
a treaty or covenant that asserts the right to health [17].
Both the ICESCR and the International Covenant on Civil
and Political Rights (ICCPR) [18] of 1966 further enu-
merate and define the rights within the UDHR, and place
enforceable obligations upon national governments to
respect, protect and fulfill each human right for the
citizens of their country. Similarly, the UN Committee
on Economic, Social and Cultural Rights published
“General Comment No. 14” in 2000, which defined what
the right to health implies, and outlined obligations for
each state: a state is required to respect the right to health
by abstaining from actions that limit or make unequal
access to “preventive, curative and palliative health ser-
vices [19]”. A state also will protect the right to health by
“ensuring equal access to health care and health care-
related services” [19]. Finally, a state is required to fulfill
the right to health by establishing “provision of health
care… and to adopt measures against environmental and
occupational health hazards and against any other threat
as demonstrated by epidemiological data [19]”.
Beyond the ICESCR, ICCPR and General Comment
14, there have been additional attempts at reaffirming
and defining not only the right to health but also corre-
sponding national and international obligations, in inter-
national human rights treaties such as the Convention
on the Rights of the Child [20], regional charters such as
the African Charter on Human and People’s Rights [21],
and in national constitutions such as that in South
Africa [22]. The Siracusa Principles, adopted in 1984
[23], have established conditions and criteria to be ad-
dressed when restricting human rights in order to avoid
abuses, such as the necessity to take decisions in accord-
ance with national laws and ensure those decisions are
neither disproportionate nor arbitrary [24]. Currently
there is also a movement supported by a broad base of
key players from the fields of human rights and public
health, with public supporters such as UN Secretary
General Ban ki-Moon and UNAIDS Executive Director
Michel Sidibé, to create a framework convention on global
health, outlining in legally binding terms the obligations of
states and related parties with regard to the right to health
and all it entails [25].
However, these existing international covenants have
not yet specifically laid out a framework for infectious
diseases that have truly global repercussions, such as tu-
berculosis. While the Siracusa Principles for instance
offer acceptable guidelines, they also have limitations. As
a result, they have not been effectively implemented in
any country that originally signed on to their adoption.
This is due mainly to three reasons. Firstly, the Siracusa
Principles were produced by the Economic and Social
Council of the United Nations (ECOSOC), which make
them mere recommendations. Indeed, the type of ‘soft
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and is not binding. Secondly, the Siracusa Declaration is
not specific to global health but more specifically targeted
to the derogation of civil and political rights, and therefore
lacks precision in this regard. Finally, the Principles refer
to the necessity to comply with national laws, which, spe-
cifically for TB do not yet exist, as explained in more de-
tail below. Therefore it appears clearly that there is a need
to go beyond the Siracusa Principles.
In addition, while we are in full support of a framework
convention for global health, we are hesitant in expecting
such a broad framework to solve the problems that a
trans-boundary disease such as TB poses to global health.
In fact, the inclusion of how articles and guidelines per-
taining to specific diseases should be included, if at all, is an
outstanding question posed by the Joint Action Learning
Initiative on National and Global Responsibilities for
Health, a key thought supporter for such a framework
convention [26]. We are therefore advocating in our opin-
ion paper that while a framework convention for global
health is necessary, that either explicit guidelines for state
actors and private sector companies specific to TB must
be included, or either a simultaneous process to negotiate
a framework convention on TB must be done, to serve as
a model for future framework conventions on specific dis-
eases, such as malaria, HIV/AIDs, non-communicable dis-
eases, and others.
Currently, we find ourselves in a strategic time, in that
the momentum from the Millennium Development Goals
that brought renewed worldwide attention to health issues
such as TB is now transitioning to a new post-2015 era
where international goals and targets for public health
have yet to be defined. The global health and human
rights communities must seize the opportunity to intro-
duce on the international stage a framework convention
that either explicitly includes TB, or one specific to only
TB, in order to capitalize on this momentum.
Discussion
Tuberculosis legislation and the right to health in Africa
We focus the discussion in this section on Africa be-
cause the continent suffers from the highest incidence
rates of TB worldwide, and most TB high burden coun-
tries are located on that continent. In the past few years,
there has been major progress towards global targets for
reduction in the burden of the disease. The 2015 MDG
target of halting and reversing TB incidence has been
achieved, with TB incidence falling globally for several
years in all 6 WHO regions, including Africa. However,
the African region, home to 11% of the world’s popula-
tion, still has approximately one quarter of the world’s
cases (255 incident cases per 100,000 on average, more
than double the global average of 122) and the highest
rates of cases and mortality relative to population. Whileprevalence and mortality rates are declining in all 6 WHO
regions, the African region is not currently on track to
meet the 2015 MDG target for prevalence or mortalitye.
The proportion of TB cases co-infected with HIV is also
highest in the African region. Overall, 37% of TB cases
were estimated to be co-infected with HIV in this region,
which accounts for 75% of TB cases among people living
with HIV worldwide.
African healthcare systems are particularly constrained
in their ability to respond to the threat posed by tuber-
culosis due to limitations such as lacking adequate facil-
ities, trained personnel, reliable drug supplies, laboratory
capacity and most importantly, access to steady funding
sources. Although the Global Fund to Fight AIDS,
Tuberculosis and Malaria (GFATM) and the President’s
Emergency Plan for AIDS Relief (PEPFAR) have donated
large sums to help address Africa’s health problems, most
of the funding has been earmarked for HIV, with a lesser
financial focus on TB. In 2013, analyses were conducted
in the context of estimates of funding needs and funding
gaps for a full response to the TB epidemic. The total
funding required in all low- and middle-income countries
was estimated to be US$ 8 billion in 2015, compared to
US$ 6 billion in 2012. The Global Fund accounted for
64% of all donor funding reported by countries during the
decade 2002–2011. Despite growth in funding from
domestic and international donor sources, National TB
Programs (NTPs) were not able to mobilize all the fund-
ing that they estimated to be needed for TB prevention,
diagnosis and treatment. Funding gaps persisted and in-
creased from US$ 257 million in 2002 to US$ 563 million
in 2011 to US$ 1 billion in 2013, with the African region
accounting for 48% of this funding gap.
In order to adequately address the threat of TB, the
WHO has taken key steps, particularly in recent years,
by promoting various interventions, including the use of
a rapid, molecular-based technology for diagnosis of TB
[27], increased investments in laboratory services, focus
on preventive therapy for HIV-infected patients and sur-
veillance of drug resistance. In line with the elaboration
of a post-2015 development framework, the WHO also
began in 2012 the process of developing a post-2015 glo-
bal TB strategy. The draft strategy includes the goal of
ending the global TB epidemic by 2035, with corre-
sponding global targets for major reductions in TB cases
and deaths by 2035. Achieving the proposed targets is
based on three strategic pillars: integrated, patient-centered
TB care and prevention; supportive systems; and intensified
research and innovation.
The WHO first declared TB a “Global Emergency” in
1993 and since then, significant efforts have been under-
taken to control the disease. This strong focus on TB
control and prevention has led to substantial gains
worldwide, including in Africa, demonstrating that with
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the disease can be curbed. However, despite the major
gains highlighted earlier, the curable disease still claims
close to 1.3 million deaths every year. What is needed
moving forward is a systematic and rigorous effort that
will simultaneously solidify the gains in TB control since
the early 1990s while also expanding to other diseases
such as HIV or malaria by strengthening health systems
generally. The experience in Africa demonstrates why an
international TB control framework is necessary and
timely in the post-2015 context. To put the situation in
the context of human rights, the vast majority of African
countries have signed on to both ICESCR and ICCPR
covenants (Figure 1). Fifty-one African countries have
agreed to the terms of the ICESCR by signing the coven-
ant, while 48 states out of 55f have ratified it. All of the
states colored yellow in Figure 1 have therefore declared
to the global community that they will respect, protect,
and fulfill the right to health for their citizens.
Given the importance of the right to health and its cor-
responding obligations across the African continent, in
these same states where incidence of a trans-boundary
disease such as TB is highest, special attention must be
made to controlling this disease in order to ensure the
right to health for all.
In research for this paper, we examined the commit-
ment of African states to implement specific health pol-
icies for TB by conducting a brief survey of heads of
National TB Programs (NTPs) in Africa. Written surveys
were sent via email to 54 NTPs and follow up phone calls
were organized when needed. Some officials declined to
answer or were unavailable during our investigation. We
gathered information for 34 countries. Figure 2 illustrates
whether African countries have explicit policies addressing
TB. Of the NTPs interviewed, all but one (Swaziland) in-
dicated that their country had either no policy addressing
TB, or only general policies regarding public health and/
or communicable diseases that are not specific to TB, but
included TB policies. Six heads of NTPs (Kenya, Namibia,
Uganda, Tunisia, Zambia and Zimbabwe) reported having
policies that address non-adherence to DOTS (Directly
Observed Therapy – Short course is the WHO-approved
treatment strategy for TB [28]) with containment (isola-
tiong in health facilities or incarcerationh). Most respon-
dents agreed that containment laws were not effectively
enforced.
The absence of clear policy surrounding TB patients’
containment illustrates the challenges governments face
with regard to isolating the illness while still protecting
individual freedoms. Although non-adherence may repre-
sent a personal choice for individuals and not simply the
failures of the health system, the contagious nature of TB
makes one individual’s non-adherence potentially life-
threatening for communities. Therefore, it is imperativethat countries organize or strengthen their enforcement of
TB policies in order to protect their populations.
In our survey, only Swaziland’s NTP reported that its
government’s legal framework included national policies
specific to tuberculosisi. Interestingly, this specific legisla-
tion does not include a section on containment for non-
adherence. However, if the international community wants
to effectively respond to the global threat of tuberculosis
in a coordinated manner and adequately help countries,
there is a need to go beyond the basic international hu-
man rights covenants and limited attempts at national TB
policies, that have so far failed to reach their goals, and to
implement an international TB control framework that
would assist countries in defining appropriate policies
and ensure that patients’ right to health is respected. The
basis for designing and implementing such a TB control
framework exists given the commitment of these African
states to protecting the human rights of their citizens, in-
cluding specifically to respect, protect, and fulfill the right
to health. In addition to governments, civil society orga-
nizations have also made a substantial positive impact
throughout the regions of Africa [29], not only by raising
awareness and improving uptake of services, but also im-
portantly by holding governments to account. Thus now
is the time for action as we are entering the post 2015-era,
particularly given the increasing burden of drug resistant
TB, as well as the lack of national TB policies that protect
the human rights of citizens, while also controlling the
spread of TB and MDR-TB.
Public health and international human rights: the case of
the FCTC
As noted above, the idea of an international framework
for global health has been proposed [25,30] in an effort to
reduce disparities and provide better coordination among
national and international stakeholders. Inspired by the
FCTC, this would certainly be notable progress as the first
treaty to provide guidelines for international regulation of
global health, and should start by addressing the critical
and trans-boundary disease burden of TB. We believe
the first such legal framework should be focused on tu-
berculosis because it is a respiratory infection that is highly
contagious, and transmission occurs while patients are
passively interacting with their surroundings simply by
breathing, rendering prevention difficult [2,31].
There are two potential ways to realize this: the first is
by ensuring that the proposed framework convention on
global health includes disease specific articles and rules on
actions that states, the private sector and other relevant
parties (as defined below) must take. This would appear to
be an attractive option, as TB is but one area where an
international human rights framework could prove benefi-
cial in motivating states actions. There is also an advan-
tage in strengthening health systems as a whole. However,
Figure 1 African states that signed or ratified the International Covenant on Economic, Social and Cultural Rights (ICESCR) and the
International Covenant on Civil and Political Rights (ICCPR).
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Figure 2 Tuberculosis legislation in African states. Specific tuberculosis-related legislation was mapped in 34 states in Africa that responded
to our written survey (out of 54). Based on responses from representatives from National Tuberculosis Programs, states were classified as either
having no tuberculosis policy (yellow), or general policies regarding public health and/or communicable diseases that could be applied to tuberculosis
(orange). The only country with a specific policy on tuberculosis (Swaziland) was included in the latter category (orange). Finally, countries that adopted
policies to quarantine or detain noncompliant tuberculosis patients appear in dashed.
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ment in a larger framework convention in a way that
does not include specific responsibilities and guidelines
such as those suggested in the following section. Therefore,
in our second and preferred option, we would propose
that, using the model of the FCTC, and building upon the
international conversation for a framework convention
on global health, that a framework convention specific
to TB be negotiated. This could be achieved either simul-
taneously as a framework convention on global health, or
separately by starting with a framework on TB where other
diseases specific targets could be built in subsequently,
either way issued by the WHO as a legally binding con-
vention. This latter option would prevent overburdening
signatory countries with a series of reforms for various
diseases that, while complementary, could possibly lead to
a financial strain on existing health systems. However,
even in the context of a framework convention specific to
TB, scarce resources would not just be committed to a
single disease, possibly at the detriment of other health
problems. We believe that the implementation of the FC
would not only focus on strengthening access to TB
services, but also lead to health systems strengthening
as a whole. For instance, better laboratory infrastruc-
ture for TB diagnosis will also benefit access to adequate
microscopy-based diagnosis to tackle diseases such as
malaria or shistosomiasis. Improved patient management,
particularly around adherence and management of lost-to
follow up will also benefit other patients with chronic dis-
eases, infectious or not, such as HIV or diabetes.
As noted above, the WHO can issue binding treaties, and
the FCTC was a significant first example of this important
authority. The FCTC requires that states implement legisla-
tion that protects their citizens from deleterious health
effects such as secondhand smoke, and design national
programs that target a reduction in nicotine addiction. The
FCTC thus has implications for member states, as well as
for private sector companies that sell tobacco internation-
ally. Though the FCTC is not a human rights treaty, it in-
cludes allusions to human rights. In keeping with human
rights norms, it also places obligations on states with re-
gard to tobacco control that are inherently a component of
a state’s responsibility to respect, protect, and fulfill the
right to health. As of September 19, 2013, 177 parties were
bound by the FCTC, representing 88% of the global popu-
lation, including 47 states in Africa [32].
The FCTC model is therefore key for future public
health treaties that address global burdens of disease. The
FCTC should serve as an aspirational model. However, we
do not recommend transposing the FCTC in its entirety
to develop the new framework since there would be inher-
ent differences between the two, mainly that the FCTC
addresses a risk factor while our proposed framework fo-
cuses on a disease. Consequently, the measures related toa disease such as TB must be more specific than currently
enforced. We believe such a framework convention as the
FCTC can be used as a model of international cooperation
with corresponding obligations on member states and the
private sector to protect the right to health for individuals
in a binding legal framework.
While it is necessary to note that defining, drafting and
negotiating such a convention can be a long and arduous
process, the reason we look to a framework convention
for TB rather than existing guidelines issued by the WHO
such as the Guidance on Ethics of Tuberculosis Prevention,
Care and Control [10], is that guidelines are just that –
suggestions on how a state or private sector company or
other related party should behave, with little enforcement
power, and often not backed by financial or other re-
sources as incentives to motivate institutions to support
their implementation at the national level. As the WHO
notes in the above referenced Guidance, there are respon-
sibilities on state actors to prevent and manage TB, which
are generally accepted and well known, but, as they state,
“TB has not yet been eradicated mostly because these re-
sponsibilities have been neglected” [10].
Finally, such a framework ‘convention with definitive
international standards for TB prevention, care and man-
agement, grounded in human rights, would benefit all
state parties involved. Controlling TB is not just in the
interest of countries where the disproportionate burden of
disease lies. With an airborne disease such as TB, and the
ease of traveling from one country to another with any
manner of illnesses (including, as we’ve seen this year,
with Ebola), controlling TB is in every country’s interests.
And those countries with the highest burdens of disease
would benefit from increased attention and support to this
disease, including financial resources that are desperately
needed (with more information on this below) [33]. Thus
despite the resources and time that negotiating such a
framework convention will require, establishing a set of
enforceable and justiciable international responsibilities
for states that would ensure a human rights-based ap-
proach to TB prevention, care and management, would be
well worth the resources expended.
An international legal framework for TB
The legal framework we are proposing would define the
rights and responsibilities of the different stakeholders
involved in TB treatment and control. Its objective is to
protect communities and the human rights of TB pa-
tients [34]. Civil societies and social movements will be
particularly critical in turning these rights commitments
into a reality on the ground.
The patients
First and foremost, it is important to protect the right of
the patients, in ensuring that they have access to equitable
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clear and complete information regarding the state of their
disease and its possible evolution both in terms of health
and legal implications. This could be achieved through
counseling from healthcare providers, or distribution of
informative brochures at the time of diagnosis. While
these are already recommended in the national guidelines,
they are not always enforced, particularly in rural settings
in low-resource countries. Many patients, including in de-
veloped countries, have suffered from the lack of precision
about their rights because of the absence or disparity of
regulations [35]. A clearly defined legal framework would
guarantee the fundamental right of all TB patients to in-
formation related to their condition and would allow them
to comprehend their need for treatment.
The first step in successful treatment outcome is ac-
curate diagnosis, and based on the most recent WHO
report, close to a third of the expected cases of TB
worldwide go undiagnosed [1]. These undetected TB pa-
tients unknowingly contribute to the spread of the air-
borne disease, and pose a threat to their communities.
While the most commonly used diagnostic tool (sputum
smear microscopy) is imperfect and can only detect on
average half of the cases, new molecular-based tools for
TB diagnosis are available, and are part of the WHO strat-
egy for increased case detection [27]. Unfortunately, des-
pite a scale up in recent years, these tools are not currently
available everywhere and most health centers, particularly
in Africa, still rely on microscopy. The framework should
include a strategy for prevention and control benefiting the
community that would involve sensitization (during mar-
ket days, in schools, during community meetings) on the
most common signs of tuberculosis, and promotion of
early diagnosis, which should be paired with an improve-
ment of diagnostic structures at health facilities. The com-
munity could directly be involved through the rollout of
Community Health Worker (CHW) programs for door-
to-door detection of TB suspects, and subsequent referral
to health centers for diagnosis. Civil society organiza-
tions should particularly be involved and empowered
to reinforce positive messages that TB is curable, and that
treatment is free. Civil society organizations should also
be mobilized to form treatment support groups within the
community to assist TB patients throughout their six-
month treatment. Furthermore, donors and governments
acknowledge that civil society benefits populations by pro-
viding a measure of accountability. Institutional goals,
such as transparency, are often cited as important reasons
for having monitoring bodies that advance citizens’ inter-
ests [29].
Based on WHO guidelines, TB patients who do not take
their medication for eight consecutive weeks or more are
classified as “defaulters” or “lost to follow up”. In order
to prevent this, a set of rules to ensure adherence andaccess must be undertaken. This can be achieved through
community-based DOTS, or the use of new mobile-health
technologies [36-38]. Given the enormous consequences
of failed TB treatment, not providing quality and access-
ible treatment to a patient can result in a violation of their
human rights. Additionally, it cannot be assumed that
any failure to take the medication is solely a fault of the
patient. Dr. Paul Farmer has completed ethnographic
studies of TB DOTS adherence in countries such as Haiti,
Peru and the United States, and has found that numerous
times a patient deemed “lost to follow up” is a negative
consequence of the public health system, rather than
any malicious conduct and neglect on the part of the
patient [39]. With that in mind, any international TB
control framework has to take into account the issues
patients face around access to treatment, and pro-
mote equitable access to effective curative treatments.
This would effectively ensure the fulfill requirement of
the framework.
If all efforts to follow up with patients have not been suc-
cessful, including patient tracing through CHWs and at-
tempts at counseling sessions, public authorities should be
able to select home confinementj with mandatory DOTS
supervised by CHWs. If the patient persists in not respect-
ing treatment requirements, public health authorities
should be able to increase the stringency of their actions
towards containment if they consider it to be a necessity
to protect the community until the patient’s completion of
treatment. Containment therefore serves the double pur-
pose of ensuring completion of treatment while also pre-
venting transmission in the community. A recent survey
carried out by the Ethics Advisory Group from members
of the International Union Against TB and Lung Disease
showed that 83% of respondents supported involuntary in-
carceration as their preferred mechanism of containment
[40]. However, we believe containment should be orga-
nized in public health facilities rather than prisons, as was
unfortunately done in the case in Kenya in 2010. Not only
would incarceration violate patients’ rights, they may also
unnecessarily place at risk the cellmates of TB patients
since infection control cannot be ensured in the prison
environment [41]. In the home or public health facility, it
is easier to protect against infection of others, and patients
are more efficiently managed by healthcare professionals,
rather than prison guards. However, we need to stress the
need to provide health facilities that are appropriate for
the treatment and care of patients who have an airborne
disease such as tuberculosis (such as adequate ventila-
tion). Examples of nosocomialk transmission of TB and
MDR-TB to healthcare staff abound [42-44]. At any time,
on the basis of the patient’s response to treatment and
their willingness to be adherent, these constraining solu-
tions should be adjusted and the patient returned to a
regular clinic-based DOTS.
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to health and guarantee a right to appeal for the patient
[45]. Though it may be a challenge for local and national
governments alike to provide adequate legal representa-
tion for their citizens regardless of socio-economic status,
it is still an imperative piece of any TB control framework.
To address this and ensure that containments are equit-
able and only required in rare circumstances where other
methods have failed, additional mechanisms need to be
built into the framework. The framework should empower
NTPs to first monitor any requests for containment,
and to ensure that each patient is adequately and fairly
treated. The NTP must monitor the authorities and pa-
tients while under containment, and provide yearly up-
dates to a coordinating body of representatives from
among the signatory countries. In the context of our pro-
posed Framework, involving counseling sessions for non-
adherent patients, and the involvement of Civil Societies
as treatment supporters in the communities, the number
of patients needing to be contained should remain very
small.
Other stakeholders
A key stakeholder group that must be considered in the
framework are pharmaceutical companies. All first and
second line drugs currently used for the treatment of
drug-susceptible TB have been developed over 40 years
ago, and are out of patent. National TB Programs there-
fore benefit from access to generic drugs of excellent
quality at affordable prices. Unfortunately, counterfeit
TB drugs are also available on the global market along-
side the generic drugs [46]. Counterfeit drugs are often
not pharmacologically adequate, and their circulation
may greatly contribute to the spread and development of
drug resistance [47]. Adherent patients may believe they
are taking the appropriate regimen when in fact the
drug dosage is too low or is uneven, which is effectively
equivalent to skipping pills [48]. Therefore, public author-
ities through national legal regulations must require stan-
dards and more testing and control over the quality of the
medicines that are imported in a country and take re-
sponsibility in banning counterfeit drugs of sub-optimal
pharmacology. Simple and affordable tests are available to
screen TB medications of substandard quality, a step that
must be taken following the drug registration and tender-
ing process in each country, before distribution to patients
[49]. The legal framework could provide suggested penal-
ties for pharmacists who dispense non-approved drugs
from these companies producing counterfeit drugs that
could lead to drug-resistance, if it is proven that the drugs
were acquired illegally outside the national supply system.
It is important to note that two new compounds, beda-
quiline and delamanid, have recently been developed
and approved for treatment of MDR-TB [50,51]. Globalpatents covering pharmaceutical companies are governed
by Trade Related Aspects of Intellectual Property Rights
(TRIPS), which applies to all World Trade Organization
(WTO) members. The TRIPS Agreement, enforced since
1995, introduced global minimum standards for pro-
tecting Intellectual Property Rights (IPR), including pat-
ents, and requires all WTO members to adapt their laws
to the minimum standard of IPR protection. However,
TRIPS also contains provisions that allow a certain degree
of flexibility for countries to accommodate their own
patent and IPR systems. Additionally, transition periods
are granted, particularly to Least Developed Countries
(LDCs). The transition periods have meant that pharma-
ceuticals or medicines patented before developing coun-
tries implemented their TRIPS obligations will not receive
patent protection, and thus generic competition is pos-
sible. National TB Programs implementing treatment regi-
men that include either of those two new compounds will
therefore also need to take steps to ensure the high quality
of the drugs purchased and dispensed to patients, should
they decide to procure generic versions of bedaquiline
or delamanid.
The basis for including private sector companies in such
an international framework convention is well proven. For
example, a 2011 UN Report on Guiding Principles on
Business and Human Rights stated that private companies
must respect human rights and therefore:
“(a) Avoid causing or contributing to adverse human
rights impacts through their own activities, and
address such impacts when they occur; and (b) Seek
to prevent or mitigate adverse human rights impacts
that are directly linked to their operations, products
or services by their business relationships, even if they
have not contributed to those impacts [52].”
The obligations of the private sector was also a notable
component in the FCTC, with private companies having
to submit to testing of their products to comply with na-
tionally defined standards for tobacco product contentl,
and comply with standards for product labelsm that at-
tempt to discourage use. The example of the FCTC and
UN recommendations on private sector responsibility
for public health should be a component integrated into
any international TB control framework.
Finally, public authorities and the government also have
a shared responsibility to assure reliable and continuous
access to quality health services. If public authorities fail
to provide basic services, how can we expect the patient
to adequately play their part? In the case of Kenya in
2010, measures were taken to limit the freedom of move-
ment of non-adherent TB patients by incarceration, but
the government failed to provide adequate structures to
provide treatment in decent conditions. Indeed, these
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ting instead of a prison, but that type of isolation facility
was not available [53]. That is why it is important that the
legal framework must hold public authorities and govern-
ments accountable. Strict guidelines as to what is appro-
priate for national TB laws to protect the patient and
also ensure that communities are not threatened by the
diseases, as well as mechanisms meant to strengthen the
primary health care system, must be included within
the framework.
Coordination mechanisms and ensuring adherence by each
country
To facilitate the governance of the obligations under the
TB control framework suggested above, a coordinating
body of representatives from among the signatory coun-
tries should be set up, under the leadership of the WHO
and the Stop TB Partnership. This body would be re-
sponsible for ensuring that signatory parties are follow-
ing the regulations within the convention, and adopting
national policies and guidelines in compliance. This
body would also, in partnership with international orga-
nizations and like-minded supporters such as interested
non-governmental and civil society organizations operat-
ing in the health and policy sectors, provide technical
support as needed to state parties to assist in drafting le-
gislation in keeping with the articles included within the
convention.
As a part of their responsibilities, this proposed body
would also review all cases of containment, benefiting
both the patient and the states. It would provide a cu-
mulative review of the processes and outcomes of such
cases conducted by a specific country over the course of
a year. This will be in addition to regular reports on each
signatory parties achievements and challenges with re-
spect to implementing the convention within their own
borders. The oversight body will therefore ensure com-
pliance with the various articles under the framework,
and annually review the status with each signatory party,
based on both a state’s annual report of activities under
the framework, to be coordinated by the NTP in each
country, as well as an external review as necessary.
Finally, an important recommendation for any such
Convention must acknowledge that, while TB is a global
disease, special considerations must be included for de-
veloping countries. A number of countries may not have
the resources to implement fully such recommendations,
particularly in the case of tracking patient follow-up, at
least in the immediate term. Article 22 of the FCTC is
relevant and should be translated into any global TB
control framework: it recommended that technical as-
sistance to each country, particularly those defined as
“developing” or with “economies in transition”, be pro-
vided in order to help countries fulfill their obligationsunder the FCTC. Such recommendation has important
repercussions for the ability of many countries in Africa
and elsewhere to adhere to such a framework conven-
tion. While status as a developing country does not ex-
cuse any state from implementing the regulations such
a TB framework would contain, it does acknowledge
that additional technical capacity and assistance may
be required.
Possible funding mechanisms
We envision that international funding streams relevant
to TB, primarily the Global Fund, would make future TB
grants contingent upon the country internalizing and
implementing the recommendations within the frame-
work convention, to act as a further incentive and en-
sure that the convention is being implemented within
states, and to provide incentive for other states that may
not have signed on to either sign the convention, or to
still adopt the proposed regulations in their own coun-
tries. We also acknowledge that the Global Fund alone
will not be able to cover the costs associated with the
adequate implementation of the provisions defined in
the Framework. Therefore, innovative funding strategies
will need to be explored. One great example is UNITAID,
which uses innovative financing to increase funding for
greater access to treatments and diagnostics for HIV/
AIDS, malaria and tuberculosis in low-income countries.
Approximately half of UNITAID’s finances come from a
levy on air tickets. A similar model could be designed,
with a financing model based on a tax on, for example,
mobile phones and tablets.
Summary
The management of TB poses global health challenges
but also ethical and legal ones. Though existing guide-
lines on TB prevention, care and control exist, further
action is needed in order to make these guidelines inter-
nationally enforceable and justiciable, which is where a
framework convention on TB control is needed. The
FCTC can serve as an example for what such a conven-
tion can look like and how it can be implemented, being
the first convention issued by the WHO. Such a frame-
work needs to establish specific procedures and secure
the rights and duties of all stakeholders.
Global management of TB is possible, if codified in
such a framework that requires that state parties change
policies and work together to control the disease both
within their own borders and internationally. It is not
just a framework that can and should be implemented in
more developed countries, but will also, through inter-
national cooperation, directly impact the lives of those
where the burden of TB is the highest. It takes the will
of the state to implement measures to increase access to
treatment, and it takes the contribution of the private
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plement this suggested framework. Successfully implement-
ing policies that address patients’ rights and communities’
well-being can have positive implications for those affected
by TB as well as other respiratory illnesses, and serve as a
basis for other internationally agreed upon and enforced
global health conventions and treaties to truly ensure the
global right to health. Drafting a framework is not a pana-
cea, but a necessary step. Public international law can be
aspirational, and we understand that there is often tension
between whether legal guidelines should reflect reality or
an ideal. We are aiming for an ideal framework that sus-
tainably impacts the global TB burden in measurable
ways, and hope to start a productive discussion that will
have tangible results benefiting TB patients and communi-
ties alike through this proposed Framework Convention
on TB.
Endnotes
aArticle 2(k) of the WHO Constitution.
bArticle 21 of the WHO Constitution.
cArticle 63 of the WHO Constitution.
dArticle 2(k) of the WHO Constitution.
eMDG tuberculosis control target: to halve the preva-
lence of tuberculosis disease and deaths between 1990 and
2015.
f55 recognized States.
gTo separate ill persons who have a communicable
disease from those who are healthy.
hSubject to confinement in prison.
iThe TB-specific legislation is part of a Public Health
Act of 1968.
jHome confinement is different from incarceration in a
state-controlled institution, which is much harder to
manage and much more likely to violate the human rights of
an individual patient. The former method allows TB patients
to choose to stay in a residential setting for their treatment.
kOriginating in a hospital.
lArticles 9 and 10 of the Framework Convention on
Tobacco Control.
mArticle 11 of the Framework Convention on Tobacco
Control.
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